Tazmetostat, an EZH2 inhibitor, was approved for advanced ES based on a basket trial with 62 patients treated, with ORR of 14.5% (9/62), median PFS of 5.5 months and median OS of 19 months. This evidence concerns the gene EZH2 and epithelioid sarcoma.